ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.
相关临床试验
10
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
10.0%
已完成
4
40.0%
Unknown
5
50.0%
暂无批准数据
- Vyome Therapeutics received Nasdaq approval for its merger with ReShape Lifesciences, set to begin trading as "HIND" on August 15, 2025. - The clinical-stage company focuses on immuno-inflammatory and rare diseases, targeting a market exceeding $100 billion in inflammatory conditions. - Vyome's existing clinical-stage assets address major unmet medical needs in the immuno-inflammatory space, developed over years of research. - The merger includes a 1-for-4 reverse stock split and positions the company to leverage opportunities between US and Indian healthcare markets.
- ReShape Lifesciences secured EU MDR and UK Conformity Assessment certification for its entire commercial portfolio of medical devices, achieving compliance well ahead of the December 31, 2027 regulatory deadline. - The certification establishes ReShape among a select group of medical device manufacturers capable of meeting the European Union's rigorous new standards for patient safety and product quality across 30 countries. - Following the announcement, ReShape's stock price surged 62% as the certification ensures uninterrupted market access for the company's obesity treatment devices including the FDA-approved Lap-Band System. - The early compliance positions ReShape to expand its product pipeline while maintaining seamless access to European markets for its weight loss and metabolic health solutions.
- ReShape Lifesciences reported Q1 2025 financial results showing revenue of $1.1 million, a 42.7% decrease from the same period in 2024, primarily due to competition from GLP-1 pharmaceutical weight-loss alternatives. - The company is progressing toward finalizing its merger with Vyome Therapeutics and asset sale to Biorad Medisys, with the S-4 recently declared effective and plans to set a record date in the near future. - ReShape strengthened its intellectual property portfolio with multiple patent allowances for its Diabetes Neuromodulation system and intragastric balloon technology, extending protection through at least 2039.
- ReShape Lifesciences presented preclinical data demonstrating their proprietary Diabetes Neuromodulation device can effectively reverse insulin-induced hypoglycemia without cardiac side effects in a swine model of Type 1 diabetes. - The technology utilizes targeted stimulation of the sub-diaphragmatic posterior vagus nerve to rapidly increase blood glucose levels during hypoglycemic episodes, offering a potential alternative to conventional treatments. - ReShape recently received a Notice of Allowance from the USPTO for a patent related to this technology, providing protection until April 2039 and strengthening their intellectual property portfolio of 62 issued or pending patents.
